A detailed history of Verition Fund Management LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Verition Fund Management LLC holds 23,527 shares of MLTX stock, worth $215,507. This represents 0.01% of its overall portfolio holdings.

Number of Shares
23,527
Previous 24,317 3.25%
Holding current value
$215,507
Previous $950,000 16.84%
% of portfolio
0.01%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$32.84 - $51.05 $25,943 - $40,329
-790 Reduced 3.25%
23,527 $1.11 Million
Q1 2025

May 15, 2025

BUY
$36.75 - $54.34 $893,649 - $1.32 Million
24,317 New
24,317 $950,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $338M
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.